Epidemiology of pancreatic cancer in Northeastern Italy: incidence, resectability rate, hospital stay, costs and survival (1990–1992)

• Published in: Digestive and liver disease 2002-10, Vol.34 (10), p.723-731
• Main Authors: Pasquali, C., Sperti, C., Filipponi, C., Pedrazzoli, S.
• Format: Article
• Language: English
• Subjects: Costs and Cost Analysis; epidemiology and survival; Female; Hospital Costs - statistics & numerical data; Humans; Incidence; Italy - epidemiology; Length of Stay - statistics & numerical data; Male; pancreatic cancer cost; Pancreatic Neoplasms - economics; Pancreatic Neoplasms - epidemiology; Pancreatic Neoplasms - surgery; Survival Rate
• ISSN: 1590-8658; 1878-3562
• DOI: 10.1016/S1590-8658(02)80024-X

Background. The incidence of pancreatic cancer and relative hospital stay and costs are not well known. Aims. To define the incidence, hospital stay and cost of pancreatic cancer in a well-defined area of Italy. Patients and Methods. Each new case of pancreatic cancer diagnosed between 1990 and 1992 among 669,703 inhabitants in the Veneto Region of Northern Italy was recorded and followed until death or for 5 years after diagnosis. Four types of hospital stay were defined. Type 1: undiagnosed pancreatic cancer; type 2: first diagnosis of pancreatic cancer, treatment excluded; type 3: main treatment; and type 4: follow-up and disease-related complications. Data were analysed for hospital stay-related procedures, costs and survival. Results. Pancreatic cancer was diagnosed in 253 patients (12.6/100,000 per year), 43 patients (17.7%) underwent surgical resection, and 93 (36.8%) palliative surgery. The mean duration of type 3 hospital stay was similar for resection, palliative and exploratory surgery. The estimated hospital cost was significantly higher for surgical resection, almost the same for palliative and exploratory surgery, and only slightly lower for medical treatment. Each patient spent a mean of 57.7 days in the hospital. The hospital mortality rate was 4.6% for surgical resection, 22. 1 % for palliative surgery, and 18.7% for exploratory laparotomy Overall, the 1-, 2-, 3- and 5 -year survival rates were 20.9%, 5.1%, 2.9% and 1.2%, respectively. Conclusions. Pancreatic cancer is an expensive, almost incurable disease. Integrated treatments in specialized Centres should reduce the mortality rate and costs.